Abstract: Methods of using microarrays to simplify analysis and characterization of genes and their function are provided. Such methods can be used to identify and characterize antibodies having binding affinity for a specific target antigen. A method of determining gene expression at the protein level by contacting an array of characterized or uncharacterized antibodies on a solid surface with one or more proteins and identifying the antibodies to which said protein(s) binds also is provided. This method can be used to compare the protein expression in two different populations of cells, such as normal cells and cancer cells or resting cells and stimulated cells. In addition, a method of determining gene expression at the protein level by contacting a microarray of nucleic acid samples derived from a variety of different sources with one or more nucleic acid probes then identifying the sample or samples to which the probe binds is provided.

Abstract: Various embodiments of methods and kits are disclosed for prognosis, detection, and/or diagnosis of toxemia in a subject patient by analyzing an aliquot of the subject patient's extracellular fluid (e.g., blood serum) that contains carrier proteins.

Abstract: Chondroitin sulfate polysaccharides with defined sulfation patterns can be synthesized. These chondroitin polysaccharides can be used to identify chondroitin sulfate binding proteins. Further, compounds that modulate the activity of chondroitin sulfate binding proteins can be identified. For example, TNF-? was found to bind specifically to CS-E and CS-E can be used to modulate the interaction of TNF-? with the TNF receptor.

Abstract: Described herein are substrates, methods, articles, and kits that are useful for removing interferents from samples for diagnostic purposes. The interferents are removed with phosphocellulose and cation exchange materials. These materials could also be used in vitro to improve the performance of a diagnostic assay or in vivo to remove the interferents.

Abstract: The invention provides an improved method for identifying and interpreting tissue specimens and/or cells derived from tissue specimens. A panel of cell-based reagents provides a number of readouts of cellular states or biomarkers that together define a profile of a diversity of cellular states or biomarkers in a tissue specimen representing the ‘systems” nature of biology. This cellular profile is interpreted using informatics tools, to identify similarities between specimens, in vivo medical conditions, and suggest options for treating medical conditions.

Abstract: A method for detecting or monitoring the presence of protein fragments, cleaved at novel cleaving sites near the N-terminal part of the collagen IX alpha 1 chain, close to the C-terminal part of the NC4 domain, and at the COL3 domain close to the NC3 domain. Neoepitope antibodies against the neoepitopes were created by the cleavages and an epitope in the cleaved N-terminal part of the NC4 domain unique to collagen IX. A diagnostic kit and antibodies useful in carrying out such methods are also presented.

Abstract: Methods for determining the efficiency of a therapeutic. In at least one embodiment of a method of determining the efficacy of a therapeutic compound, the method comprises the steps of treating a subject having a disease state with an effective amount of therapeutic compound, harvesting at least one cell from the subject following a treatment with the therapeutic compound, bringing the at least one cell into contact with a stabilizing compound capable of completely or substantially preventing the degradation or inactivation of a diagnostic marker for the disease state, analyzing the at least one stabilized cell for the at least one diagnostic marker, creating a marker profile from at least one result determined from analyzing the at least one stabilized cell, and comparing the marker profile with at least one previous marker profile to determine efficacy of the therapeutic compound on the disease state.

Abstract: The present disclosure provides immunoassays and kits for detection or quantification of an analyte of interest in a test sample that potentially contains endogenously produced autoantibodies reactive with the analyte.

Abstract: The present invention relates to the analysis of modified LDL in the context of immune complexes. In particular, ox-LDL and AGE-LDL are shown to predict the development of coronary artery disease and other micro- and macrovascular disorders, particularly in the context of diabetes.

Abstract: A diagnostic method for determining the absence or presence of a disease is provided. The method includes assaying the amount and/or types of glycopeptides in a sample from a subject, and comparing these to the amount and types of reference glycopeptides. The method may include the use of a stable isotope label, affinity selection, immunoaffinity chromatography, and glycoproteomics techniques, to identify and quantify changes in glycosylated peptides or glycosylated proteins associated with cancers such as malignant lymphoma or breast cancer, to monitor patient's response to therapy, and to monitor disease recurrence.

Abstract: A method is provided along with related reagent kits for aiding the diagnosis of IPF or other interstitial lung diseases, as well as for potential monitoring of disease progression or therapeutic response to treatment.

Abstract: A system for the detection of molecular associations, the system comprising: i) a first agent, comprising a first interacting group coupled to a first reporter component; ii) a second agent, comprising a second interacting group coupled to a second reporter component; iii) a third agent, comprising a third interacting group; iv) a modulator; and v) a detector; wherein proximity of the first and second reporter components generates a signal capable of detection by the detector; and wherein the modulator modulates the association of the second interacting group with the third interacting group; such that monitoring the signal generated by proximity of the first and second reporter components by the detector constitutes monitoring the association of the first and third agents.

Abstract: The present invention relates to a method for determining SUMOylation and utilizing said SUMOylation patterns for identifying specific interaction between different binding partners. In another aspect, the present invention relates to systems allowing the determination of SUMOylation and for determining specific interaction between binding partners. Furthermore, the present invention relates to vectors and proteins relating to SUMOylation.

Abstract: The invention relates to a method for detecting endotoxins in a sample.

Abstract: The invention relates to markers for acute myocardial infarction (AMI), particularly markers that may be used in the rapid and accurate diagnosis of AMI or reinfarction. A method of diagnosing cardiac injury comprising identifying an elevated concentration of cardiac myosin binding protein C (cMyBP-C) or a fragment thereof or myosin regulatory light chain 2 (MLC2) or a fragment thereof in a sample obtained from a subject.

Abstract: The invention provides biomarkers and combinations of biomarkers that are useful in diagnosing lung diseases such as non-small cell lung cancer or reactive airway disease. The invention also provides methods of differentiating lung disease, methods of monitoring therapy, and methods of predicting a subject's response to therapeutic intervention based on the extent of expression of the biomarkers and combinations of biomarkers. Kits comprising agents for detecting the biomarkers and combination of biomarkers are also provided.

Abstract: The invention relates to a method for the diagnostic investigation of biological samples from a person for inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where the sample is investigated for one or more proteins as markers of inflammation of the liver, in particular hepatic fibrosis and/or cirrhosis of the liver, where a concentration of the proteins which is elevated or decreased by comparison with the healthy state indicates the presence of an inflammation of the liver, in particular a hepatic fibrosis and/or cirrhosis of the liver.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects in the context of renal artery stenosis (RAS). In particular, the invention relates to using assays that detect NGAL, their use to diagnose RAS in subjects suffering from hypertension, and their use in prognosis, particularly of mortality and worsening renal function.

Abstract: The invention relates to a method for diagnosis and/or risk classification for acute coronary syndrome (ACS), in particular for acute myocardial infarct (AMI) and angina pectoris (AP) and/or a post-myocardial infarct, wherein a determination of the C-terminal pro-endothelin (CT-proET-1) or fragments and partial peptides therefrom, is carried out in combination with NT-proBNP.

Abstract: A method is disclosed for analyzing a biological sample by antibody profiling for identifying forensic samples or for detecting the presence of an analyte. In an illustrative embodiment of the invention, the analyte is a drug, such as marijuana, cocaine (crystalline tropane alkaloid), methamphetamine, methyltestosterone, or mesterolone. The method involves attaching antigens to a surface of a solid support in a preselected pattern to form an array wherein the locations of the antigens are known; contacting the array with the biological sample such that a portion of antibodies in the sample reacts with and binds to antigens in the array, thereby forming immune complexes; washing away antibodies that do not form immune complexes; and detecting the immune complexes, thereby forming an antibody profile. Forensic samples are identified by comparing a sample from an unknown source with a sample from a known source.